Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0941 DFC · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DFC (fasted) | EXPERIMENTAL | - |
| OCT (fasted) | EXPERIMENTAL | - |
| OCT (after meal) | EXPERIMENTAL | - |
| OCT (before meal) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 10 mg MK-0941 DFC (fasted) | DRUG | single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state |
| 10 mg MK-0941 OCT (after meal) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal |
| 10 mg MK-0941 OCT (before meal) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast |
| 10 mg MK-0941 OCT (fasted) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state |
Inclusion Criteria: * Males or females (of non-childbearing potential) between the ages of 18 to 70 * Participants have been diagnosed with Type 2 Diabetes * Participants are nonsmokers for at least 6 months Exclusion Criteria: * Participant should not be diagnosed with Type 1 diabetes * Particip...
MK-0941 DFC is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic that has been studied in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
MK-0941 DFC is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company conducted a Phase 1 clinical trial of the drug in adults with Type 2 Diabetes Mellitus.
MK-0941 DFC is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
MK-0941 DFC has been studied in one completed Phase 1 clinical trial, identified as NCT00567112. The trial, titled "Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)," enrolled 18 participants and was active-controlled but not double-blinded.
The molecular target of MK-0941 DFC has not been disclosed in available information. The drug is a small molecule being investigated for its effects on Type 2 Diabetes Mellitus, but its specific mechanism of action is not publicly detailed.